VBIV

VBI-1901

Glioblastoma Multiforme (GBM / glioblastoma)

Stage (next event)

Expected Date

Phase 1/2a (Data)

Q4 2020

Catalyst Info & Data Links

TITLE: VBI-1901 for Glioblastoma Multiforme (GBM / glioblastoma) - Phase 1/2A Data

  • ClinicalTrial.gov (NCT03382977) Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 1/2A Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • VBI has applied its eVLP Platform in the development of a glioblastoma multiforme (“GBM” or “glioblastoma”) therapeutic vaccine candidate. With its novel approach, VBI intends to create a GBM immunotherapy that will stimulate the patient’s own immune system to identify and kill GBM cancer cells, with the goal of creating a commercially-viable therapy that is more effective and tolerable than current treatments. VBI has initiated a multi-center, open-label, dose-escalation Phase 1/2a study to evaluate VBI-1901 in patients with recurrent GBM (Learn more HERE). 

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon